Reference Detail

Ref Type

Journal Article

PMID

(29626621)

Authors

Ma Y, Zheng X, Zhao H, Fang W, Zhang Y, Ge J, Wang L, Wang W, Jiang J, Chuai S, Zhang Z, Xu W, Xu X, Hu P, Zhang L

Title

First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.

Journal	Vol	Issue	Date	Pages	Journal Short Title
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	13	7	2018 07	968-977	J Thorac Oncol

URL

Abstract Text

AC0010 is a mutation-selective, third-generation EGFR tyrosine kinase inhibitor (TKI). This aim of this first-in-human phase I trial was to determine the maximum tolerated dose, recommended phase II dose, schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AC0010 in patients with advanced or recurrent NSCLC and acquired resistance to a first-generation EGFR TKI.Patients received escalating daily doses of AC0010 (50-600 mg) throughout 28-day cycles. A modified three-plus-three design was applied. Patients with EGFR T790M mutation were selected by dose expansion. Next-generation sequencing of plasma cell-free DNA was performed before and after treatment to determine mechanisms of anticancer activity and underlying acquired resistance.Data from 52 patients were reported. Common treatment-emergent adverse events were diarrhea (75%), skin rash (48%), and increased alanine transaminase level (44%); adverse events of grade 3 or higher were seen for increased transaminase level (12%) and skin rash (4%). The maximum tolerated dose was not reached. When all evaluated doses and patients negative for T790M were included, the overall response rate was 36.5%. At daily doses of 350 mg or higher, the overall response rate was 50.0% and the median progression-free survival estimated by the Kaplan-Meier method ranged from 14.0 to 35.6 weeks across a daily dose level from 350 mg to 600 mg. On the basis of pharmacokinetics data analysis, twice-daily administration is recommended and 300 mg twice daily is suggested as the recommended phase II dose. The cell-free DNA sequencing results from 17 patients indicate that T790M allele frequency decreased significantly after treatment with AC0010 (from 2.24 at baseline to 0 with a partial response or stable disease [p < .001]). In patients with development of resistance to AC0010, BRAF V600E mutation, ROS1 fusion, MNNG HOS Transforming gene (c-Met), and erb-b2 receptor tyrosine kinase 2 gene (ERBB2) amplification were detected but EGFR C797S mutation was not detected.AC0010 had a well-tolerated safety profile and promising antitumor activity in patients with NSCLC with acquired resistance to a first-generation EGFR TKI, supporting its continued development.

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References